Month: September 2021

Photo 1aDrill intercepts from VB21-013 showing mineralizationPhoto 1bDrill intercepts from VB21-013 showing mineralizationPhoto 1cDrill intercepts from VB21-013 showing mineralizationFigure 1Plan View of Drill HolesFigure 2Cross Section with VB21-012Figure 3Cross Section with VB21-013 and interpreted zonesDENVER, Sept. 22, 2021 (GLOBE NEWSWIRE) — Vista Gold Corp. (NYSE American and TSX: VGZ) (“Vista” or the “Company”) today announced positive results for the two remaining holes in Phase 2 of the ongoing drilling program at the Company’s 100% owned Mt Todd gold project (“Mt Todd” or the “Project”) located in Northern Territory, Australia. Highlights VB21-012 – Intersected over 100 meters of mineralization, inclusive of three zones...

VIRGINIA CITY, Nev., Sept. 22, 2021 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Mercury Clean Up LLC (“MCU”) today announced that Clean Mercury Remediation Technologies (“CMRT”), MCU’s Philippine Inc.’s joint venture, has received its remaining permit and commenced full operations in the venture’s first commercial mercury remediation system in the province of Davao D’ Oro, Philippines. “We are pleased to restart and initiate sales as we remediate mercury contamination and return the local environment back to its natural state,” said Comstock’s Executive Chairman and Chief Executive Officer, Corrado DeGasperis. Artisanal and Small Scale Gold Mining (ASGM) Mercury‐dependent ASGM uses a process known as amalgamation to dissolve gold from natural deposits. The amalgam is then typically isolated...

Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billion Effort contributes to companies’ pledge to deliver two billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2022NEW YORK and MAINZ, Germany, September 22, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countries to one billion. Consistent with the initial...

Expansion to enable Eolo to protect a growing number of fixed wireless consumer customers against the latest cyber threats. Hod Hasharon, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) — Italy’s Eolo Expands Allot NetworkSecure License to Meet Growing Demand for Cybersecurity Services Expansion to enable Eolo to protect a growing number of fixed wireless consumer customers against the latest cyber threats. HOD HASHARON, Israel, September 22, 2021 —  Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative network intelligence and security-as-a-service (SECaaS) solutions for communication service providers (CSPs) and enterprises, today announced that Italian broadband provider Eolo has decided to expand their Allot NetworkSecure capacity to meet the demand of a growing number of their fixed wireless consumer...

London, September 22, 2021 The CNH Industrial (NYSE:CNHI / MI:CNHI) Parts Logistics Centre, located in Sorocaba, São Paulo State, in the southeast of Brazil, has been awarded Bronze status in the World Class Logistics Program (WCL). This program identifies excellence in distribution and logistics processes, and the Sorocaba site is the first in the Company’s global footprint to receive this prestigious recognition. This achievement is a testament to the improvements in both the logistics practices and excellence in the services provided. The WCL evaluation utilizes a point-based methodology based on four core competencies: Positioning, Integration, Speed and Measurement. The Sorocaba depot scored 50 points, securing Bronze status. The Center achieved this ranking by demonstrating significant advances in the areas of cost, quality, productivity,...

 Top-line data from the randomized, multi-center trial are expected in Q2-2022 Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the initiation of dosing in its multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS). The Phase IIb trial is expected to recruit up to 152 severe or critical COVID-19 patients (76 AllocetraTM plus standard-of-care, 76 placebo plus standard-of-care) in clinical centers in Israel and certain European countries, and is designed to assess the safety...